摘要
目的探讨艾司奥美拉唑肠溶胶囊联合硫糖铝口服混悬液治疗慢性胃炎的疗效及安全性,旨在为临床治疗提供参考依据。方法选择东莞市长安医院2018年7月至2020年6月收治的60例慢性胃炎患者进行研究,按随机数表法分为观察组和对照组,每组30例,对照组患者在常规治疗基础上给予硫糖铝口服混悬液治疗,观察组患者在对照组治疗的基础上联合艾司奥美拉唑肠溶胶囊治疗,均连续治疗14 d。比较两组患者的临床疗效,治疗前后的临床症状、幽门螺杆菌(Hp)阳性情况、胃镜黏膜积分、血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)、T淋巴细胞亚群(CD3+、CD4+、CD4+/CD8+)的变化及不良反应。结果治疗后,观察组患者的临床治疗总有效率为93.33%,明显高于对照组的73.33%,差异有统计学意义(P<0.05);治疗后,观察组患者的腹痛、腹胀及Hp阳性患者分别为6.67%、3.33%、6.67%,明显少于对照组的26.67%、20.00%、30.00%,差异均有统计学意义(P<0.05);治疗后,观察组患者的胃镜黏膜积分、TNF-α、IL-6、CRP水平分别为(0.55±0.07)分、(14.73±2.50)ng/mL、(11.92±1.54)pg/mL、(5.89±1.06)mg/L,明显低于对照组的(0.82±0.11)分、(21.06±2.73)ng/mL、(16.75±1.60)pg/mL、(9.24±1.23)mg/L,差异均有统计学意义(P<0.05);治疗后,观察组患者的CD3+、CD4+、CD4+/CD8+分别为(68.03±4.54)%、(49.72±3.46)%、1.31±0.12,明显高于对照组的(62.22±4.83)%、(43.03±3.51)%、1.22±0.10,差异均有统计学意义(P<0.05);观察组和对照组患者治疗期间不良反应总发生率分别为16.67%和13.33%,差异无统计学意义(P>0.05)。结论艾司奥美拉唑肠溶胶囊联合硫糖铝口服混悬液治疗慢性胃炎可有效促进患者的疾病恢复,安全性好,临床治疗效果显著,值得推广应用。
Objective To study the efficacy and safety of esomeprazole enteric coated capsules combined with sucralfate oral suspension in the treatment of chronic gastritis,in order to provide reference for clinical treatment.Methods Sixty patients with chronic diseases in Dongguan Chang'an Hospital from July 2018 to June 2020 were selected.They were divided into the observation group and the control group by random number table,with 30 patients in each group.Patients in the control group were given sucralfate oral suspension on the basis of conventional treatment,while those in the observation group were given esomeprazole enteric coated capsules combined with sucralfate oral suspension on the basis of conventional treatment.All the patients were treated for 14 d continuously.The clinical efficacy,the changes of the clinical symptoms,Helicobacter pylori(Hp)positive patients,endoscopic mucosal score,serum tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),C-reactive protein(CRP),and T lymphocyte subsets(CD3+,CD4+,CD4+/CD8+)before and after treatment,and adverse reactions were compared between the two groups.Results After treatment,the total effective rate of the observation group was 93.33%,which was significantly higher than 73.33%in the control group(P<0.05);after treatment,the proportion of patients with abdominal pain,abdominal distension,and HP positive in the observation group were 6.67%,3.33%,and 6.67%,respectively,which were significantly less than 26.67%,20.00%,and 30.00%in the control group(P<0.05);after treatment,the mucosal integral,TNF-α,IL-6,and CRP levels in the observation group were(0.55±0.07)points,(14.73±2.50)ng/mL,(11.92±1.54)pg/mL,(5.89±1.06)mg/L,which were significantly lower than(0.82±0.11)points,(21.06±2.73)ng/mL,(16.75±1.60)pg/mL,(9.24±1.23)mg/L in the control group(P<0.05);after treatment,the CD3+,CD4+,CD4+/CD8+in the observation group were(68.03±4.54)%,(49.72±3.46)%,1.31±0.12,which were significantly higher than(62.22±4.83)%,(43.03±3.51)%,1.22±0.10 in the control group(P<0.05);the total incidence of adverse reactions in the observation group and control group was 16.67%and 13.33%,and the difference was not statistically significant(P>0.05).Conclusion Esomeprazole enteric coated capsules combined with sucralfate oral suspension is effective for chronic gastritis,which can effectively promote patients'disease recovery and has good safety,with remarkable clinical effect.It is worthy of popularization and application.
作者
岑光周
陈桂良
CEN Guang-zhou;CHEN Gui-liang(Department of Emergency MedicineDongguan Chang'an Hospital,Dongguan 523850,Guangdong,CHINA;Department of Gastroenterology,Dongguan Chang'an Hospital,Dongguan 523850,Guangdong,CHINA)
出处
《海南医学》
CAS
2021年第6期696-699,共4页
Hainan Medical Journal
关键词
慢性胃炎
艾司奥美拉唑肠溶胶囊
硫糖铝口服混悬液
炎症反应
安全性
Chronic gastritis
Esomeprazole enteric coated capsules
Sucralfate oral suspension
Inflammatory reaction
Safety
作者简介
通讯作者:岑光周,E-mail:01cguanzhou@126.com。
